

EXTENSION OF CLEANSING PROSPECTUS OFFER PERIOD

Wellnex Life Limited (**ASX: WNX**) advises that it is extending the Closing Date of the Offer pursuant to its Cleansing Prospectus dated 7 March 2024 (as extended to 31 October 2024 via ASX announcement dated 30 September 2024) to 29 November 2024, so as to facilitate the secondary trading of those shares to be issued.

An updated timetable is set out below.

Event	Date
Lodgement of Prospectus with ASIC and ASX	7 March 2024
Opening Date	7 March 2024
Closing Date (5:00pm Sydney time)	29 November 2024
Expected date of allotment of New Shares	4 December 2024
Expected date of quotation of New Shares	5 December 2024

This timetable is indicative only. The Company reserves the right to vary the dates above without prior notice, subject to compliance with the Corporations Act and Listing Rules, which may have a consequential effect on the other dates.

Terms defined in this announcement have the same meaning as given in the Cleansing Prospectus.

-ENDS-

This ASX announcement has been authorised by the Board of Wellnex Life Limited (ASX:WNX).

For further information, please contact:

Wellnex Life Limited (ASX:WNX)

George Karafotias

Chief Executive Officer

P: +61 3 8399 9419

E: george.k@wellnexlife.com.au

About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/